CARISMA THERAPEUTICS INC (CARM) Stock Income Statement
NASDAQ:CARM - Nasdaq - US14216R1014 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 19.96M | 19.63M | 14.92M | 40.00M | 26.54M | |||
| Operating Expenses | 71.97M | 81.81M | 103.65M | 26.38M | -2.14M | |||
| Research and Development | 51.37M | 59.67M | 74.13M | 38.59M | 25.31M | |||
| Selling, General, and Administrative Expenses | 20.60M | 22.14M | 29.52M | 39.79M | 29.39M | |||
| Operating Income | -52.00M | -62.18M | -88.73M | 13.62M | 28.68M | |||
| Interest Income/Expense | 1.24M | 1.70M | 1.85M | 1.85M | N/A | |||
| Other Income/Expense | N/A | N/A | N/A | 300.00K | -60.00K | |||
| Non Recurring Items | N/A | N/A | N/A | -39.53M | -37.23M | |||
| Income Before Taxes | -50.77M | -60.48M | -86.88M | -23.76M | -8.61M | |||
| Income Tax | N/A | N/A | N/A | -3.88M | -8.27M | |||
| Net Income | -50.77M | -60.48M | -86.88M | -19.88M | -340.00K | |||
| EBITDA | -49.68M | -58.83M | -85.89M | 13.63M | 28.77M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.22 | -1.46 | -2.59 | -1.98 | -0.04 | |||
| Non GAAP EPS | -1.22 | -1.46 | -3.47 | -2.00 | 0.66 | |||
| Statistics | ||||||||
| Profit Margin | -254.28% | -308.05% | -582.34% | -49.70% | -1.28% | |||
| Operating Profit Margin | -260.48% | -316.72% | -594.75% | 34.05% | 108.06% | |||
All data in USD